Novavax, Inc. (NASDAQ: NVAX) is making a run for the top in the market this morning. The gains come after the company issued its financial results.
While the financial report wasn’t anything amazing, investors seem to be excited about upcomming events that could drive serious value. Today, we’ll talk about:
- What we saw from the report;
- what we’re seeing from NVAX stock as a result; and
- what we’ll be watching for ahead.
NVAX Announces Financial Results And Corporate Update
As mentioned above, Novavax is having a great day in the market today after announcing its financial results. Here’s what we saw from the report:
- Losses – During the fourth quarter, NVAX generated a loss of $49.3 million. That works out to a loss of $0.13 per share. Analysts expected for the loss to come in at $0.12 per share.
- Revenue – During the quarter, the company generated revenue in the amount of $6.1 million. This figure fell short of the $7.9 million that analysts were expecting to see.
While the financial results weren’t all that great, the company excited investors with upcomming events. First and foremost, the company is continuing discussions with regulatory agencies to assess opportunities for submission of license applications for ResVax.
Moreover, in the second quarter, the company plans on reaching an agreement with the FDA. This agreement will revolve around the company’s proposed Phase 3 study design for NanoFlu, which will utilize accelerated approval criteria.
The company also said that it plans on presenting ResVax Phase 3 data at the 37th Annual Meeting fo the European Society for Pediatric Infectious Diseases. This presentation will take place on May 7, 2019.
In a statement, Stanley C. Erck, President and CEO at NVAX, had the following to offer:
In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both. Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Novavax, while financial results weren’t great, the upcoming catalysts are hard to ignore.
Considering this, it’s not surprising to see that investors are excited and that the stock is on a move up. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:48), NVAX is trading at $0.64 per share after a gain of $0.084 per share or 15.19% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the story surrounding the company’s continued work to develop ResVax and NanoFlu. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!